GSK Signs Global Licensing Deal With Alfasigma For Linerixibat

2026-03-10 00:26:51

Abstract generation in progress

GSK has signed a global licensing agreement with Alfasigma for linerixibat, an investigational ileal bile acid transporter (IBAT) inhibitor for cholestatic pruritus in primary biliary cholangitis (PBC). Alfasigma will gain worldwide exclusive rights to develop, manufacture, and commercialize linerixibat, which has Orphan Drug Designation and positive Phase III trial results. GSK will receive an upfront payment of $300 million, additional milestone payments upon regulatory approvals, and tiered double-digit royalties on net sales.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.